Posted by Michael Wonder on 17 Apr 2023
Daratumumab in combination with bortezomib and dexamethasone for the treatment of patients with previously treated multiple myeloma
17 April 2023 - NICE has published final draft guidance on the use of daratumumab in combination with bortezomib and dexamethasone for the treatment of patients with previously treated multiple myeloma.
Daratumumab with bortezomib and dexamethasone is recommended as an option for the treatment of adults with multiple myeloma, only if they have had just one previous line of treatment and
- It included lenalidomide or the use of lenalidomide is unsuitable as a second-line treatment
- Janssen provides daratumumab according to the commercial arrangement
